QAB Inc.

QAB's medical device is proposed to be the first commercially available unit capable of producing quantified autologous bio-therapeutics.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Vail, CO, USA
  • Currency USD
  • Employees 3
  • Website greyledgebiotech.com

Company Summary

The QAB Device is designed to be the first commercially available medical device with the capability to produce quantified autologous Platelet Rich Plasma and Bone Marrow Cell Concentrate. The value of the device to clinicians is that it will allow them to specify a particular concentration of platelets or cells and also provide a record of the concentration actually delivered. From this platform dose-response relationships can be established.

Team

  • David Christopher Karli
    Executive President

    QAB was founded by David C. Karli, MD, MBA of The Steadman Clinic in Vail, Colorado. Dr. Karli's clinical interest in regenerative medicine and the development of non-surgical interventions for a variety of conditions led him to develop a novel, laboratory-based model for processing autologous blood and bone marrow tissues to produce injectable or surgically implantable bioactive products. Dr. Karli attended Medical School at the University of Ma

Advisors

  • Susan Hodson
    Lawyer
    Unconfirmed
    Paul Gustafson
    Accountant
    Unconfirmed

Previous Investors

  • Sterling Williams (accredited Angel Investor)
    Unconfirmed
    David Karli, MD, MBA (accredited Angel Investor)
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free